Fungal disease
Conditions
Interventions
Prevention group:posaconazole oral suspension
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
13 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Voluntary test, the patient or his authorized client agree to participate in the clinical trial and sign the informed consent form; 2. Aged >= 13 years, gender is not limited; 3. prothrombin activity (PTA) = 3 days Vascular or abdominal tube >=10 days other factors Use >=2 broad-spectrum antibiotics, (glycopeptides/carbapenems/B lactamaseinhibitors/aminoglycosides) and continue to use >= 4 days Long-term stay in ICU (>=15 days) Neutropenia (WBC=0.3mg/kg/d, or equivalent, the dose >=3 weeks), (except for patients with allergic bronchopulmonary aspergillosis) High MELD score (>=30) Have a history of fungal infections
Exclusion criteria
Exclusion criteria: 1. Patients allergic to posaconazole oral suspension; 2. Patients who cannot eat; 3. Pregnancy / breastfeeding; 4. Expected survival time <72 hours; 5. Patients who did not sign the informed consent form; 6. History of drug abuse or alcohol dependence; 7. Patients with glucose-galactose malabsorption (the drug suspension contains glucose); 8. Any predictable increase in patient risk or other factors that can interfere with clinical trial outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood concentration; | — |
Countries
China
Contacts
Public ContactYalin Dong, Tianyan Chen
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed